


NMS Labs 2300 Stratford Ave Willow Grove, PA 19090

AP-237



Sample Type: Seized Material

Latest Revision: **September 16, 2019** Date Received: **August 16, 2019** Date of Report: **September 16, 2019**

1. GENERAL INFORMATION

IUPAC Name:	1-[4-[(E)-cinnamyl]piperazin-1-yl]butan-1-one
InChI String:	InChI=1S/C17H24N2O/c1-2-7-17(20)19-14-12-18(13-15-19)11-6- 10-16-8-4-3-5-9-16/h3-6,8-10H,2,7,11-15H2,1H3/b10-6+
CFR:	Not Scheduled (09/2019)
CAS#	17730-82-4
Synonyms:	Bucinnazine, 1-butyryl-4-cinnamylpiperazine
Source:	Department of Homeland Security
Appearance:	White Solid Material

Important Note: All identifications were made based on evaluation of analytical data (GC-MS and LC-QTOF) in comparison to analysis of acquired reference material.

Prepared By: Alex J. Krotulski, MSFS, Melissa F. Fogarty, MSFS, D-ABFT-FT, and Barry K. Logan, PhD, F-ABFT

2. CHEMICAL AND PHYSICAL DATA

2.1 CHEMICAL DATA

Form	Chemical	Molecular	Molecular Ion	Exact Mass
	Formula	Weight	[M ⁺]	[M+H] ⁺
Base	$C_{17}H_{24}N_2O$	272.4	272	273.1961

3. BRIEF DESCRIPTION

AP-237 (Bucinnazine) is classified as a synthetic opioid. AP-237 is structurally distinct from fentanyl, its analogues, and other synthetic opioids previously reported. AP-237 is an opioid used therapeutically; although not prescribed within the United States. Based on its recent emergence and potential for abuse within the United States and worldwide, AP-237 has been categorized as a Novel Psychoactive Substance (NPS). 2-Methyl AP-237, previously reported through this network, is a structurally similar analogue of AP-237; both are not scheduled substances in the United States. AP-237 was found to be active with several literature reports characterizing its pharmacological properties.¹⁻³

4. ADDITIONAL RESOURCES

- Nishimura, N.; Kiuchi, M.; Kanetake, Y.; Takahashi, T. (1970). "Clinical evaluation of a new analgesic agent Ap-237". *Masui*. 19 (6): 653–6. https://www.ncbi.nlm.nih.gov/pubmed/4916908
- 2. Carrano, R. A.; Kimura, K. K.; McCurdy, D. H. (1975). "Analgesic and tolerance studies with AP-237, a new analgesic". Arch Int Pharmacodyn Ther. 213 (1): 41–57. <u>https://www.ncbi.nlm.nih.gov/pubmed/1156018</u>
- 3. Carrano, R. A.; Kimura, K. K.; Landes, R. C.; McCurdy, D. H. (1975). "General pharmacology of a new analgesic-AP-237". Arch Int Pharmacodyn Ther. 213 (1): 28–40. <u>https://www.ncbi.nlm.nih.gov/pubmed/1156016</u>


https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/AP-237-ID-2048-19_report.pdf


https://www.caymanchem.com/product/26484

5. QUALITATIVE DATA


5.1 GAS CHROMATOGRAPHY MASS SPECTROMETRY (GC-MS)

Testing Performed At:	NMS Labs (Willow Grove, PA)
Sample Preparation:	Acid/Base extraction
Instrument:	Agilent 5975 Series GC/MSD System
Column:	Zebron TM Inferno TM ZB-35HT (15 m x 250 µm x 0.25 µm)
Carrier Gas:	Helium (Flow: 1 mL/min)
Temperatures:	Injection Port: 265 °C
	Transfer Line: 300 °C
	MS Source: 230 °C
	MS Quad: 150 °C
	Oven Program: 60 °C for 0.5 min, 35 °C/min to 340 °C for 6.5 min
Injection Parameters:	Injection Type: Splitless
	Injection Volume: 1 µL
MS Parameters:	Mass Scan Range: 40-550 m/z
	Threshold: 250
Retention Time:	7.084 min
Standard Comparison:	Reference material for AP-237 (Batch: 0545936-4) was purchased from Cayman Chemical (Ann Arbor, MI, USA). Analysis of this standard resulted in positive identification of the analyte in the exhibit as AP-237, based on retention time (7.062 min) and mass spectral data. (<u>https://www.caymanchem.com/product/26484</u>)





Additional peaks present in chromatogram: internal standards (3.212 min and 6.286 min)




EI (70 eV) Mass Spectrum (Top) and 10x (Bottom): AP-237

5.2 LIQUID CHROMATOGRAPHY QUADRUPOLE TIME OF FLIGHT MASS SPECTROMETRY (LC-QTOF)

Testing Performed At:	The Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation (Willow Grove, PA)		
Sample Preparation:	1:100 dilution of acid/base extract in mobile phase		
Instrument:	Sciex TripleTOF® 5600+, Shimadzu Nexera XR UHPLC		
Column:	Phenomenex® Kinetex C18 (50 mm x 3.0 mm, 2.6 µm)		
Mobile Phase:	A: Ammonium formate (10 mM, pH 3.0)		
	B: Methanol/acetonitrile (50:50)		
	Flow rate: 0.4 mL/min		
Gradient:	Initial: 95A:5B; 5A:95B over 13 min; 95A:5B at 15.5 min		
Temperatures:	Autosampler: 15 °C		
	Column Oven: 30 °C		
	Source Heater: 600 °C		
Injection Parameters:	Injection Volume: 10 µL		
QTOF Parameters:	TOF MS Scan Range: 100-510 Da		
	Precursor Isolation: SWATH® acquisition (27 windows)		
	Fragmentation: Collison Energy Spread (35±15 eV)		
	MS/MS Scan Range: 50-510 Da		
Retention Time:	5.36 min		
Standard Comparison:	Reference material for AP-237 (Batch: 0545936-4) was purchased from Cayman Chemical (Ann Arbor, MI, USA). Analysis of this standard resulted in positive identification of the analyte in the exhibit as AP-237, based on retention time (5.38 min) and mass spectral data. (https://www.caymanchem.com/product/26484)		

Chromatogram: AP-237



Additional peaks present in chromatogram: internal standards (4.89 min and 7.25 min)



